AI medical "technology + scene" ecosystem continues to improve, HEC CJ PHARM (01558) is expected to lead the new wave of innovative drug research and development.

The deep cooperation of technology giants injects new vitality into the application of artificial intelligence (AI) in the field of medicine. In addition to scenarios such as pathological diagnosis and medical imaging, the combination of AI and drug development is becoming the focus of industry breakthroughs. As one of the pioneers in the domestic AI medical field, HEC CJ PHARM (01558) chooses to fully explore the enormous potential of AI technology in empowering pharmaceutical innovation through a combination of self-research and cooperation, providing a benchmark paradigm of "cost reduction and efficiency enhancement" for the innovative drug industry. AI-driven research and development paradigm innovation Drug development has long been known for its "high cost, long cycle, high risk." According to statistics, in traditional research and development scenarios, it takes an average of 10 to 15 years and costs over $20 billion for an original new drug to go from discovery to market. How to break through this dilemma? Guangdong Hec Technology Holding chooses to reconstruct the entire drug development process with AI technology at its core. On December 16th last year, Guangdong Hec Technology Holding's AI-driven first-class new drug, the first small molecule innovative drug HEC169584, was approved for clinical trials for non-alcoholic steatohepatitis (NASH). HEC169584 is the first candidate drug obtained by Guangdong Hec Technology Holding through its AI-driven small molecule drug design platform. The team used the HEC-GEN model (a molecular fragment generation model based on sparse graph attention neural networks) to generate a large number of structurally diverse ligand molecules based on the THR- target pocket, and evaluated their affinity with the target protein using molecular docking technology. Through these AI technologies, the company finally determined the candidate drug HEC169584 with good in vivo and in vitro efficacy, pharmaceutical properties, and safety. Previous preclinical research results showed that HEC169584 has high in vitro activity against THR- cells, strong liver targeting with a liver-blood ratio of 24.5 (AUC ratio), which can reduce the impact on tissues such as the thyroid axis and heart. In a mouse model of NASH with liver fibrosis, it showed improvements in liver function, blood lipids, liver lipids, liver inflammation, liver NAFLD activity score, and liver fibrosis. Guangdong Hec Technology Holding's exploration and success in AI-assisted innovation drug development. At present, there are no similar drugs on the market in China, and HEC169584 is expected to quickly advance to clinical trials, bringing new treatment options for patients. In addition to independent research and development with AI large models to assist innovative research and development, Guangdong Hec Technology Holding is also strengthening external cooperation and continuously providing its own AI-driven research and development capabilities. Starting in 2023, Guangdong Hec Technology Holding has been collaborating with Huawei Cloud on AI drug development, optimizing high-precision drug molecular attributes and drug structures, creating a one-stop out-of-the-box large model drug development platform from drug discovery to pharmaceutical processes. The core advantage of the Huawei Cloud Pangu large model lies in its powerful data processing and generation capabilities. By learning from massive compound databases, protein structure data, and clinical trial results, the Pangu model can accurately predict the binding ability, toxicological properties, and pharmaceutical properties of molecules to targets. The research and development team of Guangdong Hec Technology Holding leverages this technology to increase the efficiency of small molecule virtual screening by 20 times and design efficiency by 30%, significantly accelerating the discovery process of candidate drugs. Policy dividends released, AI healthcare enters a golden development period The explosive growth of AI healthcare is inseparable from strong policy support. In November 2024, the National Health Commission and three other departments jointly issued the "Reference Guide for AI Applications in the Health Industry," clearly listing "AI + drug development" as a key breakthrough area and encouraging enterprises to use AI technology to accelerate the development of innovative drugs. Industry analysis indicates that this policy not only provides strategic opportunities for pioneers like Guangdong Hec Technology Holding but also promotes the deep integration of AI technology and the medical industry. With the support of favorable policies, the market size of the domestic AI healthcare industry is experiencing rapid growth. Frost & Sullivan predicts that by 2033, the market size of China's AI healthcare will increase from 88 billion yuan in 2023 to 315.7 billion yuan, with a compound annual growth rate of 43.1%. The cooperation between Guangdong Hec Technology Holding and Huawei embodies the ecological layout of "technology + scenario." Huawei, relying on the core technology system of "Pangu large model + Ascend AI framework + cloud computing," provides comprehensive support from underlying computing power to application layers for Guangdong Hec Technology Holding. With its profound experience in pharmaceutical research and clinical resources, Guangdong Hec Technology Holding continuously expands the application scenarios of AI technology. At the turning point of the explosion of AI healthcare, the exploration of Guangdong Hec Technology Holding provides valuable experience for the industry. Its success lies not only in technological breakthroughs but also in pioneering the collaborative research and development model of "AI + expert experience" AI is responsible for screening and preliminary design, scientists focus on key decisions and optimization verification, and the combination releases an exponential innovation efficiency. Driven by multiple factors including policies, technology, and capital, AI healthcare is moving from concept to large-scale implementation. The deep cooperation between Guangdong Hec Technology Holding and Huawei not only brings higher options for patients but also accelerates the promotion of AI technology in the field of pharmaceutical innovation.The efficient treatment plan provides a key engine for the industrial upgrade of China Meheco Group. It can be foreseen that with the continuous evolution of AI technology, the wave of intelligentization in the medical industry will sweep through every corner, and the pioneers of AI medical treatment are expected to enjoy the huge dividends brought by the AI medical era in advance.Cmo ests hoy?